QTTB Q32 Bio Inc. - Common Stock
$15.44
가격 · 8월 19, 2026
기준 재무 정보 8월 5, 2026
52주 범위
$2–$24
63% of range
애널리스트 평점
BUY
11 analysts
목표 주가
$43
+177% upside
P/E (TTM)
6.4
ROE
200.3%
순이익률
55.5%
QTTB 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위
가격
$15.44
시가총액
$198M
P/E (TTM)
6.4
EPS (TTM)
$2.42
매출 (TTM)
$54M
배당 수익률
—
ROE
200.3%
부채/자본
—
52주 범위
$2 – $24
QTTB 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의
Configure
10년 성과 매출, 순이익, 마진 및 EPS 추세
매출 및 순이익
$54M
2018-12-31
→
2025-12-31
EPS
$2.42
2021-12-31
→
2025-12-31
잉여현금흐름
$-34M
2018-12-31
→
2025-12-31
마진
55.5%
가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?
지표
5년 추세
QTTB
동종업계 중앙값
P/E (TTM)
6.4
16.6
P/S (TTM)
3.7
9.4
P/B
4.7
2.4
Price / FCF (주가 / FCF)
-5.9
—
수익성 총, 영업 및 순이익률; ROE, ROA, ROIC
지표
5년 추세
QTTB
동종업계 중앙값
Operating Margin (영업이익률)
31.4%
—
Net Profit Margin (순이익률)
55.5%
-298.0%
ROA
38.7%
-38.4%
ROE
200.3%
-63.7%
ROIC
40.2%
—
재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성
지표
5년 추세
QTTB
동종업계 중앙값
Current Ratio (유동비율)
4.9
3.9
Quick Ratio (당좌 비율)
4.3
—
성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR
지표
5년 추세
QTTB
동종업계 중앙값
Revenue CAGR 3Y (매출 CAGR 3년)
155.9%
—
Revenue CAGR 5Y (매출 CAGR 5년)
81.8%
—
자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율
지표
5년 추세
QTTB
동종업계 중앙값
QTTB 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력
매수
11 명의 애널리스트
- 적극 매수 3 27.3%
- 매수 7 63.6%
- 보유 1 9.1%
- 매도 0 0.0%
- 적극 매도 0 0.0%
12개월 목표 주가
4 명의 애널리스트 · 2026-08-18
중앙값
$38.00
평균
$42.75
← 모든 목표가 하회
$15.44
저가
$36.00
고가
$59.00
중앙값 목표
$38.00
+146.2%
평균 목표
$42.75
+177.0%
실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일
평균 서프라이즈
1.00%
| 기간 | EPS Actual | EPS 예상 | 서프라이즈 |
|---|---|---|---|
| 2026년 6월 30일 | $-0.44 | $-0.55 | 0.11% |
| 2026년 3월 31일 | $-0.54 | $-0.69 | 0.15% |
| 2025년 12월 31일 | $3.65 | $-0.88 | 4.5% |
| 2025년 9월 30일 | $-0.60 | $-1.21 | 0.61% |
| 2025년 6월 30일 | $-0.78 | $-1.00 | 0.22% |
| 2025년 3월 31일 | $-0.90 | $-1.25 | 0.35% |
동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업
| 티커 | 시가총액 | P/E | 매출 YoY | 순이익률 | ROE | 매출 총이익률 |
|---|---|---|---|---|---|---|
| QTTB | $43M | 1.4 | — | 55.5% | 200.3% | — |
| ZURA | — | — | — | — | — | — |
| EVMN | $540M | -1.5 | 85.7% | -529.8% | -401.2% | — |
| CCCC | $185M | -1.5 | 1.0% | -292.1% | -48.8% | — |
| MPLT | $773M | -0.9 | — | — | -151.1% | — |
| CABA | $220M | -1.0 | — | — | -115.5% | — |
| OCGN | $422M | -5.6 | 8.8% | -1537.4% | 1488.8% | — |
| LRMR | $317M | -2.2 | — | — | -167.4% | — |
| PBYI | $300M | 9.8 | -0.91% | 13.6% | 26.5% | — |
| RZLT | $388M | -4.6 | — | — | -56.9% | — |
전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름
손익계산서 14
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54M | $0 | $-7M | $3M | $34M | $3M | $2M | $5M | |
| R&D Expense | $19M | $48M | $32M | $98M | $93M | $100M | $89M | $48M | |
| SG&A Expense | $18M | $18M | $10M | $38M | $37M | $33M | $22M | $17M | |
| Operating Expenses | $37M | $66M | $42M | $136M | $130M | $133M | $112M | $65M | |
| Operating Income | $17M | $-66M | $-48M | $-133M | $-96M | $-130M | $-110M | $-60M | |
| Other Non-op | $1M | $4M | $1M | $134M | $185.0K | $2M | $6M | $4M | |
| Pretax Income | $30M | $-46M | $-53M | $1M | $-96M | · | · | · | |
| Income Tax | $0 | $21.0K | $318.0K | $715.0K | $0 | $0 | $0 | $0 | |
| Net Income | $30M | $-48M | $-54M | $-5M | $-96M | $-129M | $-104M | $-56M | |
| EPS (Basic) | $2.42 | $-5.12 | $-153.96 | $-0.09 | $-1.73 | · | · | · | |
| EPS (Diluted) | $2.42 | $-6.58 | $-153.96 | $-0.09 | $-1.73 | · | · | · | |
| Shares (Basic) | 12,300,568 | 9,320,884 | 349,060 | 57,399,762 | 55,283,318 | · | · | · | |
| Shares (Diluted) | 12,314,796 | 9,657,696 | 349,060 | 57,399,762 | 55,283,318 | · | · | · | |
| EBITDA | $17M | $-66M | · | $-133M | $-96M | $-130M | $-110M | $-62M |
대차대조표 23
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $48M | $78M | $26M | $34M | $108M | $217M | $54M | $38M | |
| Short-term Investments | · | $0 | $0 | $141M | · | · | · | · | |
| Prepaid Expense | $7M | $4M | $3M | $6M | $7M | $2M | $4M | $7M | |
| Other Current Assets | $20.0K | $396.0K | $83.0K | · | · | · | · | · | |
| Current Assets | $55M | $82M | $29M | $181M | $192M | $220M | $267M | $222M | |
| PP&E (Net) | $979.0K | $1M | $2M | $1M | $2M | $37M | $43M | $36M | |
| PP&E (Gross) | $3M | $3M | $3M | $7M | $8M | $53M | $51M | $38M | |
| Accum. Depreciation | $2M | $1M | $966.0K | $6M | $6M | $16M | $8M | $2M | |
| Other Non-current Assets | $0 | $116.0K | $5M | · | · | · | · | · | |
| Total Assets | $62M | $92M | $47M | $228M | $212M | $264M | $311M | $259M | |
| Accounts Payable | $879.0K | $3M | $3M | $1M | $2M | $5M | $3M | $16M | |
| Accrued Liabilities | $4M | $7M | $10M | · | · | · | · | · | |
| Current Liabilities | $11M | $16M | $14M | $23M | $17M | $23M | $12M | $23M | |
| Capital Leases | $5M | $6M | $6M | $28M | $24M | $13M | · | · | |
| Other Non-current Liabilities | $0 | $55M | $55M | · | · | · | · | · | |
| Total Liabilities | $20M | $87M | $119M | $50M | $42M | $68M | $52M | $63M | |
| Common Stock | $2.0K | $2.0K | $1.0K | $6.0K | $6.0K | $5.0K | $4.0K | $3.0K | |
| Paid-in Capital | $247M | $240M | $4M | $608M | · | · | · | · | |
| Retained Earnings | $-205M | $-235M | $-187M | $-429M | $-424M | $-328M | $-200M | $-96M | |
| AOCI | · | $0 | $0 | $-404.0K | $-7.0K | $0 | $183.0K | $-77.0K | |
| Stockholders' Equity | $42M | $6M | $-183M | $-131M | $170M | $196M | $259M | $196M | |
| Liabilities + Equity | $62M | $92M | $47M | $228M | $212M | $264M | $311M | $259M | |
| Shares Outstanding | 12,858,047 | 12,197,615 | 359,569 | 57,483,910 | 57,150,274 | 50,265,575 | 45,116,742 | 37,358,526 |
현금 흐름 11
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $5M | $4M | $1M | $13M | $17M | $13M | $8M | $3M | |
| Deferred Tax | · | $100.0K | $300.0K | · | · | · | · | · | |
| Restructuring | · | · | $10M | · | · | · | · | · | |
| Operating Cash Flow | $-34M | $-68M | $-19M | $-114M | $-110M | $-94M | $-91M | $-43M | |
| CapEx | $0 | $75.0K | $5.0K | $1M | $2M | $4M | $22M | $25M | |
| Investing Cash Flow | $7M | $20M | $-5.0K | $37M | $-51M | $205M | $-52M | $-122M | |
| Stock Issued | $0 | $42M | $0 | $0 | $50M | · | $135M | · | |
| Net Stock Activity | $0 | $42M | · | $0 | $50M | · | $135M | · | |
| Financing Cash Flow | $-3M | $95M | $406.0K | $596.0K | $52M | $53M | $158M | $151M | |
| Net Change in Cash | · | · | $5M | $-76M | $-108M | $164M | $15M | $-13M | |
| Free Cash Flow | $-34M | $-68M | · | $-115M | $-112M | $-98M | $-113M | $-68M |
수익성 7
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 31.4% | · | · | -4154.6% | -282.4% | -4821.0% | -6599.2% | -1671.1% | |
| Net Margin | 55.5% | · | · | -156.0% | -281.9% | -4762.9% | -6237.4% | -1553.1% | |
| Pretax Margin | 55.5% | · | · | 37.3% | · | · | · | · | |
| EBITDA Margin | 31.4% | · | · | -4154.6% | -282.4% | -4821.0% | -6599.2% | -1671.1% | |
| ROA | 38.7% | -68.5% | · | -2.3% | -40.3% | -44.8% | -36.5% | -28.8% | |
| ROE | 200.3% | -398.3% | · | -2.6% | -52.0% | -70.3% | -40.2% | -28.0% | |
| ROIC | 40.2% | -1165.3% | · | -30.2% | · | · | · | · |
유동성 및 지급능력 2
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.9 | 5.0 | · | 8.0 | 11.1 | 9.7 | 21.5 | 8.7 | |
| Quick Ratio | 4.3 | 4.7 | · | 1.5 | 6.3 | 9.6 | 4.3 | 1.5 |
효율성 1
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.0 | · | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
성장률 3
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | · | -90.6% | 1157.2% | · | · | · | |
| Revenue CAGR 3Y | 155.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 81.8% | · | · | · | · | · | · | · |
가치 평가 (TTM) 10
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $54M | $0 | $-7M | $3M | $34M | $3M | $2M | $5M | |
| Net Income TTM | $30M | $-48M | $-54M | $-5M | $-96M | $-129M | $-104M | $-56M | |
| Market Cap | $43M | $42M | · | $1.30B | $3.74B | $10.21B | $16.81B | $15.04B | |
| P/E | 1.4 | -0.5 | -0.1 | -252.0 | -37.9 | · | · | · | |
| P/S | 0.8 | · | · | 406.4 | 110.2 | 3780.5 | 10090.3 | 2825.3 | |
| P/B | 1.0 | 7.4 | · | 7.3 | 22.1 | 52.1 | 65.0 | 77.2 | |
| P / Tangible Book | 1.0 | 7.4 | · | · | 22.1 | 52.1 | · | · | |
| P / Cash Flow | -1.3 | -0.6 | · | -11.5 | -34.1 | -108.3 | -184.0 | -353.3 | |
| P / FCF | -1.3 | -0.6 | · | -11.3 | -33.4 | -104.2 | -148.5 | -222.8 | |
| Earnings Yield | 72.9% | -191.3% | -1406.8% | -0.40% | -2.6% | · | · | · |
손익계산서 14
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $-15M | $2M | $3M | $3M | $802.0K | $802.0K | |
| R&D Expense | $4M | $3M | $3M | $4M | $5M | $7M | $11M | $14M | $13M | $10M | $8M | $7M | $8M | $8M | $27M | $26M | |
| SG&A Expense | $5M | $5M | $5M | $4M | $4M | $5M | $4M | $4M | $5M | $5M | $3M | $2M | $2M | $2M | $8M | $8M | |
| Operating Expenses | $9M | $8M | $8M | $8M | $9M | $12M | $15M | $19M | $18M | $15M | $11M | $10M | $10M | $10M | $35M | $34M | |
| Operating Income | $-9M | $-8M | $46M | $-8M | $-9M | $-12M | $-15M | $-19M | $-18M | $-15M | $-26M | $-8M | $-7M | $-7M | $-34M | $-33M | |
| Other Non-op | $319.0K | $113.0K | $115.0K | $188.0K | $-318.0K | $1M | $358.0K | $1M | $2M | $158.0K | $196.0K | $84.0K | $165.0K | $578.0K | $1M | $1M | |
| Pretax Income | · | · | $58M | $-7M | $-9M | $-11M | $-14M | $-18M | $-16M | $1M | $-27M | $-14M | $-6M | $-7M | $-33M | $-32M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $21.0K | $0 | $0 | $0 | $383.0K | $-65.0K | $0 | $0 | $-403.0K | $46.0K | |
| Net Income | $-9M | $-8M | $58M | $-7M | $-9M | $-11M | $-14M | $-18M | $-17M | $1M | $-27M | $-14M | $-6M | $-7M | $-34M | $-34M | |
| EPS (Basic) | $-0.44 | $-0.54 | $4.70 | $-0.60 | $-0.78 | $-0.90 | $-3.27 | $-1.46 | $-1.42 | $1.03 | $-76.91 | $-40.52 | $-16.69 | $-19.84 | $-0.60 | $-0.59 | |
| EPS (Diluted) | $-0.44 | $-0.54 | $4.70 | $-0.60 | $-0.78 | $-0.90 | $2.63 | $-1.46 | $-1.42 | $-6.33 | $-76.91 | $-40.52 | $-16.69 | $-19.84 | $-0.58 | $-0.59 | |
| Shares (Basic) | 20,342,345 | 14,095,371 | -24,335,204 | 12,240,542 | 12,197,615 | 12,197,615 | -15,715,032 | 12,076,412 | 11,964,224 | 995,280 | -689,787 | 346,288 | 347,936 | 344,623 | -114,712,971 | 57,447,192 | |
| Shares (Diluted) | 20,342,345 | 14,095,371 | -24,320,976 | 12,240,542 | 12,197,615 | 12,197,615 | -16,717,120 | 12,076,412 | 11,964,224 | 2,334,180 | -689,787 | 346,288 | 347,936 | 344,623 | -115,308,584 | 57,447,192 | |
| EBITDA | $-9M | $-8M | · | $-8M | $-9M | $-12M | · | $-19M | $-18M | $-15M | · | $-31M | $-31M | $-28M | · | $-33M |
대차대조표 23
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $106M | $51M | $48M | $49M | $55M | $65M | $78M | $89M | $98M | $116M | $26M | $29M | $77M | $39M | $34M | $43M | |
| Short-term Investments | · | · | · | · | · | · | · | $0 | · | · | $0 | $74M | $50M | $111M | · | · | |
| Prepaid Expense | $3M | $6M | $7M | $2M | $3M | $3M | $4M | $5M | $4M | $3M | $3M | $3M | $4M | $4M | $6M | $12M | |
| Other Current Assets | $19.0K | $20.0K | $20.0K | $24.0K | $77.0K | $93.0K | $396.0K | $229.0K | $51.0K | $67.0K | $83.0K | · | · | · | · | · | |
| Current Assets | $110M | $57M | $55M | $51M | $58M | $69M | $82M | $94M | $112M | $138M | $29M | $107M | $131M | $154M | $181M | $213M | |
| PP&E (Net) | $804.0K | $889.0K | $979.0K | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $0 | $845.0K | $1M | $1M | $1M | |
| PP&E (Gross) | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $0 | $7M | $7M | $7M | $8M | |
| Accum. Depreciation | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $966.0K | $0 | $7M | $6M | $6M | $7M | |
| Other Non-current Assets | · | · | $0 | $0 | $570.0K | $444.0K | $116.0K | $40.0K | $1M | $1M | $5M | · | · | · | · | · | |
| Total Assets | $116M | $64M | $62M | $58M | $66M | $79M | $92M | $105M | $124M | $152M | $47M | $140M | $169M | $198M | $228M | $263M | |
| Accounts Payable | $2M | $653.0K | $879.0K | $973.0K | $910.0K | $3M | $3M | $1M | $2M | $5M | $3M | $8M | $3M | $4M | $1M | $5M | |
| Accrued Liabilities | $4M | $4M | $4M | $4M | $4M | $5M | $7M | $9M | $11M | $20M | $10M | · | · | · | · | · | |
| Current Liabilities | $5M | $11M | $11M | $11M | $12M | $15M | $16M | $14M | $17M | $33M | $14M | $25M | $23M | $19M | $23M | $25M | |
| Capital Leases | $5M | $5M | $5M | $5M | $5M | $5M | $6M | $6M | $6M | $6M | $6M | $27M | $27M | $27M | $28M | $28M | |
| Other Non-current Liabilities | · | · | $0 | $55M | $55M | $55M | $55M | $55M | $55M | $55M | $55M | · | · | · | · | · | |
| Total Liabilities | $10M | $17M | $20M | $76M | $78M | $83M | $87M | $86M | $91M | $104M | $119M | $52M | $50M | $46M | $50M | $54M | |
| Common Stock | $3.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $1.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | |
| Paid-in Capital | $327M | $259M | $247M | $244M | $243M | $242M | $240M | $239M | $237M | $235M | $4M | $614M | $612M | $610M | · | · | |
| Retained Earnings | $-222M | $-213M | $-205M | $-263M | $-255M | $-246M | $-235M | $-221M | $-203M | $-186M | $-187M | $-526M | $-493M | $-458M | $-429M | $-395M | |
| AOCI | · | · | · | $0 | $0 | $0 | · | $-1.0K | $-1.0K | $-5.0K | $0 | $-36.0K | $-88.0K | $-182.0K | $-404.0K | $-457.0K | |
| Stockholders' Equity | $106M | $46M | $42M | $-18M | $-12M | $-4M | $6M | $18M | $34M | $49M | $-183M | $88M | $119M | $152M | $178M | $209M | |
| Liabilities + Equity | $116M | $64M | $62M | $58M | $66M | $79M | $92M | $105M | $124M | $152M | $47M | $140M | $169M | $198M | $228M | $263M | |
| Shares Outstanding | 23,736,600 | 14,629,463 | 12,858,047 | 12,304,352 | 12,197,615 | 12,197,615 | 12,197,615 | 12,138,869 | 11,995,206 | 11,929,520 | 359,569 | 57,902,210 | 57,798,133 | 57,794,767 | 57,483,910 | 57,480,610 |
현금 흐름 10
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $417.0K | $521.0K | $-4M | $-2M | $296.0K | $3M | $3M | |
| Restructuring | · | · | · | $0 | $0 | $900.0K | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-3M | $-6M | $-6M | $-4M | $-11M | $-12M | $-11M | $-20M | $-22M | $-15M | $-11M | $42M | $2M | $-12M | $-27M | $-25M | |
| CapEx | · | · | $0 | $0 | · | · | $2.0K | $58.0K | $15.0K | $0 | $0 | $-223.0K | $-224.0K | $5.0K | $9.0K | $6.0K | |
| Investing Cash Flow | $0 | $0 | $7M | $0 | $0 | $0 | $-2.0K | $10M | $10M | $97.0K | $0 | $-92M | $-31M | $-5.0K | $18M | $-108M | |
| Stock Issued | $0 | $10M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $42M | $0 | $0 | $0 | $0 | · | · | |
| Net Stock Activity | · | $10M | · | · | · | $0 | · | · | · | $42M | · | · | · | · | · | · | |
| Financing Cash Flow | $59M | $9M | $-2M | $-2M | · | · | $317.0K | $997.0K | $-6M | $99M | $76.0K | $178.0K | $-120.0K | $15.0K | $32.0K | $124.0K | |
| Net Change in Cash | · | · | · | · | · | · | · | · | · | · | · | $-48M | $37M | $5M | $-9M | $-133M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-15M | · | · | · | $-26M | · | · |
수익성 7
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 3706.5% | 4021.9% | · | 3444.1% | 3229.2% | 3296.0% | · | · | · | · | · | · | -8705.1% | -3430.3% | · | -4097.5% | |
| Net Margin | 3636.6% | 3963.0% | · | 3358.6% | 3341.2% | 2973.3% | · | · | · | · | · | · | -9899.4% | -3596.5% | · | -4205.2% | |
| Pretax Margin | · | · | · | 3358.6% | 3341.2% | 2973.3% | · | · | · | · | · | · | -8278.2% | -3247.1% | · | -3939.3% | |
| EBITDA Margin | 3706.5% | 4021.9% | · | 3444.1% | 3229.2% | 3296.0% | · | · | · | · | · | · | -8705.1% | -3430.3% | · | -4097.5% | |
| ROA | -9.8% | -10.7% | · | -9.1% | -10.0% | -9.5% | · | -14.4% | -11.6% | 0.59% | · | -16.4% | -15.4% | -11.3% | · | -13.7% | |
| ROE | -19.1% | -36.0% | · | 9658.8% | -89.2% | -49.3% | · | -33.0% | -22.2% | 1.0% | · | -22.2% | -19.5% | -13.8% | · | -16.6% | |
| ROIC | · | · | · | 41.1% | 75.0% | 304.6% | · | -102.8% | -53.5% | -30.4% | · | -35.1% | -25.8% | -18.1% | · | -15.7% |
유동성 및 지급능력 2
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 20.3 | 5.4 | · | 4.6 | 5.1 | 4.7 | · | 6.5 | 6.5 | 4.2 | · | 4.2 | 5.7 | 8.3 | · | 8.4 | |
| Quick Ratio | 19.7 | 4.8 | · | 4.4 | 4.8 | 4.5 | · | 6.2 | 5.7 | 3.5 | · | 4.1 | 5.5 | 8.1 | · | 1.7 |
효율성 1
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | -0.0 | -0.0 | · | -0.0 | -0.0 | -0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
가치 평가 (TTM) 10
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2M | $2M | · | $2M | $2M | $2M | · | $2M | $5M | $8M | · | $9M | $8M | $5M | · | $4M | |
| Net Income TTM | $-33M | $-36M | · | $-46M | $-55M | $-45M | · | $-48M | $-36M | $-26M | · | $-60M | $-75M | $22M | · | $-1M | |
| Market Cap | $302M | $94M | · | $24M | $18M | $20M | · | $542M | $215M | $203M | · | $1.22B | $921M | $1.07B | · | $1.67B | |
| P/E | -5.4 | -2.3 | · | -0.5 | -0.3 | -0.2 | · | -0.9 | -0.3 | -0.2 | · | -0.3 | -0.4 | -1.0 | · | -579.6 | |
| P/S | 162.7 | 50.5 | · | 13.1 | 9.8 | 10.8 | · | 291.4 | 42.5 | 25.4 | · | 138.4 | 118.7 | 200.2 | · | 408.0 | |
| P/B | 2.9 | 2.0 | · | -1.3 | -1.5 | -5.0 | · | 29.6 | 6.4 | 4.2 | · | 13.8 | 7.7 | 7.1 | · | 8.0 | |
| P / Tangible Book | 2.9 | 2.0 | · | · | · | · | · | 29.6 | 6.4 | 4.2 | · | 13.8 | 7.7 | 7.1 | · | 8.0 | |
| P / Cash Flow | · | -14.8 | · | · | · | -1.6 | · | · | · | -14.0 | · | · | · | -41.1 | · | · | |
| P / FCF | · | · | · | · | · | · | · | · | · | -14.0 | · | · | · | -40.8 | · | · | |
| Earnings Yield | -18.5% | -43.9% | · | -188.9% | -306.0% | -612.7% | · | -111.5% | -361.9% | -489.3% | · | -368.7% | -236.2% | -104.4% | · | -0.17% |
재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년
손익계산서
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 매출 | $54M | $0 | $-7M | $3M | $34M |
| 영업이익률 % | 31.4% | — | — | -4154.6% | -282.4% |
| 순이익 | $30M | $-48M | $-54M | $-5M | $-96M |
| 희석 EPS | $2.42 | $-6.58 | $-153.96 | $-0.09 | $-1.73 |
대차대조표
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 유동비율 | 4.9 | 5.0 | — | 8.0 | 11.1 |
| 당좌 비율 | 4.3 | 4.7 | — | 1.5 | 6.3 |
현금 흐름
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 잉여현금흐름 | $-34M | $-68M | — | $-115M | $-112M |
나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목
📊
중요한 지표를 선택하세요 — 위 전체 기본 재무제표의 아무 행 옆에 있는 ➕를 클릭하세요.
선택 항목이 저장되어 모든 티커에서 유지됩니다.
기관 투자자 (13F) 77개의 제출자 · $280.5M 전체 · 기준일 2026년 6월 30일
분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.
기관 활동 — Q2 2026 대 이전 분기
| 신규 포지션 | 청산 포지션 | 증가함 | 감소 | 순주식 변동 |
|---|---|---|---|---|
| 33 (+25 이전 분기 대비) | 8 (0 이전 분기 대비) | 14 (+1 이전 분기 대비) | 14 (+4 이전 분기 대비) | +13.3M |
Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.
| 기관 | 가치 | 주식 | % 추적된 13F 중 | 유형 |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | $52,590,554 | 4,127,987 | 18.75% | 주식 |
| Boxer Capital Management, LLC | $40,122,209 | 3,149,310 | 14.30% | 주식 |
| Atlas Venture Life Science Advisors, LLC | $34,615,930 | 2,717,106 | 12.34% | 주식 |
| BVF INC/IL | $29,939,000 | 2,350,000 | 10.67% | 주식 |
| RA CAPITAL MANAGEMENT, L.P. | $29,715,502 | 2,332,457 | 10.59% | 주식 |
| Point72 Asset Management, L.P. | $14,949,065 | 1,173,396 | 5.33% | 주식 |
| Opaleye Management Inc. | $11,860,940 | 931,000 | 4.23% | 주식 |
| Logos Global Management LP | $10,192,000 | 800,000 | 3.63% | 주식 |
| SummitTX Capital, L.P. | $9,348,281 | 733,774 | 3.33% | 주식 |
| VANGUARD CAPITAL MANAGEMENT LLC | $6,609,550 | 518,803 | 2.36% | 주식 |
| Ikarian Capital, LLC | $5,478,200 | 430,000 | 1.95% | 주식 |
| Woodline Partners LP | $3,646,341 | 286,212 | 1.30% | 주식 |
| AMERICAN CENTURY COMPANIES INC | $3,474,860 | 272,752 | 1.24% | 주식 |
| Sanofi | $3,109,617 | 244,083 | 1.11% | 주식 |
| ACORN CAPITAL ADVISORS, LLC | $2,754,019 | 216,171 | 0.98% | 주식 |
| Ikarian Capital, LLC | $2,548,000 | 200,000 | 0.91% | 풋 옵션 |
| RENAISSANCE TECHNOLOGIES LLC | $2,288,104 | 179,600 | 0.82% | 주식 |
| JANE STREET GROUP, LLC | $1,686,164 | 132,352 | 0.60% | 주식 |
| MONIMUS CAPITAL MANAGEMENT, LP | $1,682,139 | 132,036 | 0.60% | 주식 |
| BOOTHBAY FUND MANAGEMENT, LLC | $1,661,640 | 130,427 | 0.59% | 주식 |
| CITADEL ADVISORS LLC | $1,537,247 | 120,663 | 0.55% | 주식 |
| GEODE CAPITAL MANAGEMENT, LLC | $1,273,455 | 99,923 | 0.45% | 주식 |
| MARSHALL WACE, LLP | $854,153 | 67,045 | 0.30% | 주식 |
| VANGUARD FIDUCIARY TRUST CO | $843,605 | 66,217 | 0.30% | 주식 |
| BOOTHBAY FUND MANAGEMENT, LLC | $780,962 | 61,300 | 0.28% | 풋 옵션 |
| Carlyle Group Inc. | $769,020 | 60,363 | 0.27% | 주식 |
| STATE STREET CORP | $665,206 | 52,214 | 0.24% | 주식 |
| TWO SIGMA INVESTMENTS, LP | $631,675 | 49,582 | 0.23% | 주식 |
| Quadrature Capital Ltd | $463,685 | 36,396 | 0.17% | 주식 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $440,970 | 34,613 | 0.16% | 주식 |
| DAFNA Capital Management LLC | $419,095 | 32,896 | 0.15% | 주식 |
| Knott David M Jr | $387,449 | 30,412 | 0.14% | 주식 |
| Affinity Asset Advisors, LLC | $353,879 | 27,777 | 0.13% | 주식 |
| Squarepoint Ops LLC | $303,085 | 23,790 | 0.11% | 주식 |
| NORTHERN TRUST CORP | $301,059 | 23,631 | 0.11% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $297,377 | 23,342 | 0.11% | 주식 |
| MANGROVE PARTNERS IM, LLC | $282,191 | 22,150 | 0.10% | 주식 |
| DIMENSIONAL FUND ADVISORS LP | $255,857 | 20,083 | 0.09% | 주식 |
| LPL Financial LLC | $231,486 | 18,170 | 0.08% | 주식 |
| UBS Group AG | $183,698 | 14,419 | 0.07% | 주식 |
| Balyasny Asset Management L.P. | $157,237 | 12,342 | 0.06% | 주식 |
| ExodusPoint Capital Management, LP | $144,421 | 11,336 | 0.05% | 주식 |
| MILLENNIUM MANAGEMENT LLC | $139,223 | 10,928 | 0.05% | 주식 |
| XTX Topco Ltd | $138,535 | 10,874 | 0.05% | 주식 |
| Vanguard Global Advisers, LLC | $61,458 | 4,824 | 0.02% | 주식 |
| Nuveen Asset Management, LLC | $54,758 | 15,918 | 0.02% | 주식 |
| MORGAN STANLEY | $54,132 | 4,249 | 0.02% | 주식 |
| FMR LLC | $43,163 | 3,388 | 0.02% | 주식 |
| CITIGROUP INC | $36,793 | 2,888 | 0.01% | 주식 |
| BlackRock, Inc. | $25,047 | 1,966 | 0.01% | 주식 |
| Private Wealth Asset Management, LLC | $21,658 | 1,700 | 0.01% | 주식 |
| Arax Advisory Partners | $14,154 | 1,111 | 0.01% | 주식 |
| FEDERATED HERMES, INC. | $13,377 | 1,050 | 0.00% | 주식 |
| Rockefeller Capital Management L.P. | $7,351 | 577 | 0.00% | 주식 |
| JONES FINANCIAL COMPANIES LLLP | $6,585 | 500 | 0.00% | 주식 |
| VANGUARD GROUP INC | $6,358 | 1,915 | 0.00% | 주식 |
| Russell Investments Group, Ltd. | $5,784 | 454 | 0.00% | 주식 |
| BNP PARIBAS FINANCIAL MARKETS | $3,860 | 303 | 0.00% | 주식 |
| EverSource Wealth Advisors, LLC | $3,058 | 240 | 0.00% | 주식 |
| ACADIAN ASSET MANAGEMENT LLC | $2,779 | 218,234 | 0.00% | 주식 |
| NISA INVESTMENT ADVISORS, LLC | $2,115 | 166 | 0.00% | 주식 |
| Truvestments Capital LLC | $2,064 | 162 | 0.00% | 주식 |
| OSAIC HOLDINGS, INC. | $1,579 | 124 | 0.00% | 주식 |
| Allworth Financial LP | $1,376 | 108 | 0.00% | 주식 |
| SBI Securities Co., Ltd. | $1,198 | 94 | 0.00% | 주식 |
| Clearstead Advisors, LLC | $854 | 67 | 0.00% | 주식 |
| Caitong International Asset Management Co., Ltd | $573 | 45 | 0.00% | 주식 |
| Federation des caisses Desjardins du Quebec | $484 | 38 | 0.00% | 주식 |
| GROUP ONE TRADING LLC | $433 | 34 | 0.00% | 주식 |
| CWM, LLC | $250 | 39 | 0.00% | 주식 |
| Cambridge Investment Research Advisors, Inc. | $230 | 18,081 | 0.00% | 주식 |
| HRT FINANCIAL LP | $203 | 15,949 | 0.00% | 주식 |
| HARBOUR INVESTMENTS, INC. | $140 | 11 | 0.00% | 주식 |
| MERCER GLOBAL ADVISORS INC /ADV | $25 | 2 | 0.00% | 주식 |
| AdvisorNet Financial, Inc | $25 | 2 | 0.00% | 주식 |
| DANSKE BANK A/S | $13 | 1 | 0.00% | 주식 |
| ROYAL BANK OF CANADA | $0 | 28 | 0.00% | 주식 |
회사 내부자 29 명의 내부자 · 13 임원 · 18 이사
| 내부자 | 역할 | 마지막 활동 | 보유 주식 수 | 매수 12개월 | 매도 12개월 | 순매수/매도 12개월 |
|---|---|---|---|---|---|---|
| Jodie Pope Morrison | CEO | 2026년 7월 16일 A | 353,104 | 0 | 3 | $-141,391 |
| Albert Seymour | President and Chief Executive Officer | 2023년 9월 6일 M | 150,874 | 0 | 0 | $0 |
| Lee Kalowski | CFO and President | 2026년 7월 16일 A | 142,443 | 0 | 3 | $-57,038 |
| Paul Alloway | Former President and Chief Operating Officer of Homology Medicines, Inc. | 2024년 3월 25일 S | 2,596 | 0 | 0 | $0 |
| Timothy P Kelly | Chief Operating Officer | 2022년 2월 24일 A | 2,224 | 0 | 0 | $0 |
| Siyamak Rasty | Chief Operating Officer | 2019년 7월 9일 S | 222,707 | 0 | 0 | $0 |
| Shelia M. Violette | Chief Scientific Officer | 2026년 7월 16일 A | 130,569 | 0 | 2 | $-18,078 |
| Jason Campagna | Chief Medical Officer | 2025년 2월 24일 A | 37,500 | 0 | 0 | $0 |
| Charles Michaud Jr | Former Vice President, Corporate Controller and Treasurer of Homology Medicines, Inc. | 2024년 3월 25일 S | 927 | 0 | 0 | $0 |
| Julie Jordan | Chief Medical Officer | 2023년 8월 3일 M | 7,496 | 0 | 0 | $0 |
| Michael Lee Blum | Chief Commercial Officer | 2023년 2월 23일 A | 13,538 | 0 | 0 | $0 |
| Bradford W Smith | Chief Financial and Business Officer and Treasurer | 2023년 2월 23일 A | 14,219 | 0 | 0 | $0 |
| Gabriel Cohn | Chief Medical Officer | 2022년 1월 1일 M | 2,629 | 0 | 0 | $0 |
| Diyong Xu | 이사 | 2026년 6월 12일 A | 625,000 | 2 | 0 | $15,000,000 |
| David S. Grayzel | 이사 | 2026년 6월 12일 A | — | 0 | 0 | $0 |
| Sven Ante Lundberg | 이사 | 2026년 6월 12일 A | — | 0 | 0 | $0 |
| Isaac Manke | 이사 | 2026년 6월 12일 A | 53,521 | 0 | 0 | $0 |
| Arthur Tzianabos | 이사 | 2026년 6월 12일 A | 7,983 | 0 | 0 | $0 |
| Mark T Iwicki | 이사 | 2026년 6월 12일 A | — | 0 | 0 | $0 |
| Mary Thistle | 이사 | 2026년 6월 12일 A | — | 0 | 0 | $0 |
| Kathleen Laporte | 이사 | 2026년 6월 12일 A | — | 0 | 0 | $0 |
| Jeffrey V. Poulton | 이사 | 2023년 6월 14일 A | — | 0 | 0 | $0 |
| Alise Reicin | 이사 | 2023년 6월 14일 A | — | 0 | 0 | $0 |
| Matthew R Patterson | 이사 | 2023년 6월 14일 A | — | 0 | 0 | $0 |
| Steven Gillis | 이사 | 2023년 6월 14일 A | 6,068,695 | 0 | 0 | $0 |
| Kush Parmar | 이사 | 2022년 6월 15일 A | 181,435 | 0 | 0 | $0 |
| Richard J. Gregory | 이사 | 2022년 6월 15일 A | 10,806 | 0 | 0 | $0 |
| Cameron Wheeler | 이사 | 2019년 6월 6일 A | — | 0 | 0 | $0 |
| Mahendra Shah | 이사 | 2018년 4월 2일 A | 909,742 | 0 | 0 | $0 |
SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당
행동주의자 및 5% 이상 소유자 4 보유
SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.
| 제출자 | 제출됨 | 지분 | 상태 | 목적 | 제출 |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC, ORBIMED CAPITAL GP VII LLC, OrbiMed Genesis GP LLC ×5 제출 서류 | 2026년 7월 20일 | 13.90% | 수정본 | — | SEC |
| Atlas Venture Fund X, L.P., ATLAS VENTURE ASSOCIATES X, L.P., Atlas Venture Associates X, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC, Atlas Venture Opportunity Fund II, L.P., Atlas Venture Associates Opportunity II, L.P., Atlas Venture Associates Opportunity II, LLC, Atlas Venture Opportunity Fund Ill, L.P., Atlas Venture Associates Opportunity III, L.P., Atlas Venture Associates Opportunity III, LLC ×2 제출 서류 | 2026년 5월 28일 | 3.60% | 수정본 | — | SEC |
| Acorn Bioventures, L.P., Acorn Capital Advisors, GP, LLC, Anders Hove | 2024년 4월 4일 | — | 최초 제출 | M&A / 매각 | SEC |
| Deerfield Mgmt III, L.P., Deerfield Private Design Fund III, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Mgmt HIF, L.P., Deerfield Management Company, L.P., James E. Flynn ×5 제출 서류 | 2020년 5월 1일 | — | 최초 제출 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF 보유 현황 8 ETF 보유
가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.
| 펀드 | 비중 | 단위 | 기준일 | 출처 |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0.70% | 10,132 SH | 2026년 8월 8일 | 일간 |
| IWC · iShares Trust | 0.03% | 29,465 SH | 2026년 8월 8일 | 일간 |
| AVUV · AMERICAN CENTURY ETF TRUST | 0.01% | 128,510 NS | 2026년 5월 31일 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.00% | 14,652 NS | 2026년 4월 30일 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0.00% | 314 NS | 2026년 5월 31일 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 119,269 SH | 2026년 8월 8일 | 일간 |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 389,115 SH | 2026년 8월 8일 | 일간 |
| DFSV · Dimensional ETF Trust | 0.00% | 490 NS | 2026년 4월 30일 | N-PORT |